Download PDF
Semin Respir Crit Care Med 2015; 36(01): 003-016
DOI: 10.1055/s-0034-1396906
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections

J. S. Davis
1   Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
2   Department of Infectious Diseases, John Hunter Hospital, Newcastle, New South Wales, Australia
,
S. van Hal
3   Department of Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Sydney, Australia
4   Antibiotic Resistance and Mobile Elements Group, University of Western Sydney, Sydney, Australia
,
S. Y. C. Tong
1   Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
5   Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Northern Territory, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
02 February 2015 (online)

   Permissions and Reprints

Abstract

Outcomes from methicillin-resistant Staphylococcus aureus (MRSA) infections are relatively poor, at least in part due to the limitations of vancomycin (the current standard treatment for MRSA). Combination antibiotic treatment for MRSA infections is an attractive alternative as it could address most of vancomycin's shortcomings, including poor tissue penetration, slow bacterial killing, and emerging resistance in some strains of MRSA. However, the theoretical promise of combination therapy for MRSA infections has not been borne out in most in vitro and animal studies. Multiple combinations have been tested and have been either antagonistic, indifferent, or have had conflicting findings in various studies. This includes combinations of two primarily active agents (such as vancomycin plus daptomycin or linezolid), or the addition of gentamicin or rifampin to either vancomycin or daptomycin. However, hope on this front has come from an unexpected quarter. Although MRSA is by definition inherently resistant to nearly all β-lactam antibiotics, this class of drugs has consistently shown evidence of synergy with either daptomycin or vancomycin in over 25 separate in vitro studies, and a limited number of animal and human observational studies. However, there are currently insufficient data to recommend β-lactam combination therapy in routine clinical use. Results of current and planned randomized controlled trials of this strategy are awaited.

Keywords

methicillin-resistant Staphylococcus aureus - combination antibiotic therapy - vancomycin - daptomycin
 

  • References

  • 1 Turnidge JD, Kotsanas D, Munckhof W , et al; Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 2009; 191 (7) 368-373
    PubMedGoogle Scholar
  • 2 Dantes R, Mu Y, Belflower R , et al; Emerging Infections Program–Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013; 173 (21) 1970-1978
    PubMedGoogle Scholar
  • 3 Köck R, Becker K, Cookson B , et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010; 15 (41) 19688
    PubMedGoogle Scholar
  • 4 Liu C, Bayer A, Cosgrove SE , et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55
    CrossrefPubMedGoogle Scholar
  • 5 Fowler Jr VG, Boucher HW, Corey GR , et al; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355 (7) 653-665
    CrossrefPubMedGoogle Scholar
  • 6 Wilcox MH, Tack KJ, Bouza E , et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48 (2) 203-212
    CrossrefPubMedGoogle Scholar
  • 7 Wunderink RG, Niederman MS, Kollef MH , et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54 (5) 621-629
    CrossrefPubMedGoogle Scholar
  • 8 Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40 (10) 2428-2430
    PubMedGoogle Scholar
  • 9 Jacqueline C, Caillon J, Le Mabecque V , et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51 (4) 857-864
    CrossrefPubMedGoogle Scholar
  • 10 Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47 (1) 418-420
    CrossrefPubMedGoogle Scholar
  • 11 Singh SR, Bacon III AE, Young DC, Couch KA. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53 (10) 4495-4497
    CrossrefPubMedGoogle Scholar
  • 12 Jones RN, Anderegg TR, Deshpande LM. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains. Diagn Microbiol Infect Dis 2002; 43 (1) 87-90
    CrossrefPubMedGoogle Scholar
  • 13 Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47 (9) 3002-3004
    CrossrefPubMedGoogle Scholar
  • 14 Patel R, Piper KE, Rouse MS, Steckelberg JM. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000; 44 (12) 3438-3440
    CrossrefPubMedGoogle Scholar
  • 15 Bernardo K, Pakulat N, Fleer S , et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48 (2) 546-555
    CrossrefPubMedGoogle Scholar
  • 16 Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195 (2) 202-211
    CrossrefPubMedGoogle Scholar
  • 17 Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42 (5) 729-730
    CrossrefPubMedGoogle Scholar
  • 18 Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 2013; 1277: 139-158
    CrossrefPubMedGoogle Scholar
  • 19 Nadrah K, Strle F. Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections. Chemother Res Pract 2011; 2011: 619321
    PubMedGoogle Scholar
  • 20 Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42 (11) 1652-1653
    CrossrefPubMedGoogle Scholar
  • 21 Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering Jr RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50 (4) 1581-1585
    CrossrefPubMedGoogle Scholar
  • 22 van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30 (5) 603-610
    CrossrefPubMedGoogle Scholar
  • 23 Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9 (10) 617-624
    CrossrefPubMedGoogle Scholar
  • 24 Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50 (3) 1079-1082
    CrossrefPubMedGoogle Scholar
  • 25 Tsuji BT, Rybak MJ. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis 2006; 54 (1) 73-77
    CrossrefPubMedGoogle Scholar
  • 26 Antony SJ. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 2006; 38 (4) 293-295
    CrossrefPubMedGoogle Scholar
  • 27 Hiramatsu K, Aritaka N, Hanaki H , et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350 (9092) 1670-1673
    CrossrefPubMedGoogle Scholar
  • 28 Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009; 34 (1) 8.e1-8.e9
    PubMedGoogle Scholar
  • 29 Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54 (12) 1699-1709
    CrossrefPubMedGoogle Scholar
  • 30 Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22 (12) 1517-1523
    CrossrefPubMedGoogle Scholar
  • 31 Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006; 57 (3) 573-576
    CrossrefPubMedGoogle Scholar
  • 32 Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005; 55 (6) 995-1002
    CrossrefPubMedGoogle Scholar
  • 33 Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009; 63 (3) 485-488
    CrossrefPubMedGoogle Scholar
  • 34 Silvestri C, Cirioni O, Arzeni D , et al. In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Eur J Clin Microbiol Infect Dis 2012; 31 (8) 1759-1764
    CrossrefPubMedGoogle Scholar
  • 35 Parra-Ruiz J, Bravo-Molina A, Peña-Monje A, Hernández-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J Antimicrob Chemother 2012; 67 (11) 2682-2685
    CrossrefPubMedGoogle Scholar
  • 36 Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother 2010; 54 (12) 5187-5192
    CrossrefPubMedGoogle Scholar
  • 37 Kelesidis T, Humphries R, Ward K, Lewinski MA, Yang OO. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn Microbiol Infect Dis 2011; 71 (3) 286-290
    CrossrefPubMedGoogle Scholar
  • 38 Brown J, Freeman III BB. Combining quinupristin/dalfopristin with other agents for resistant infections. Ann Pharmacother 2004; 38 (4) 677-685
    CrossrefPubMedGoogle Scholar
  • 39 Fuchs PC, Barry AL, Brown SD. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal. Antimicrob Agents Chemother 2001; 45 (9) 2662-2665
    CrossrefPubMedGoogle Scholar
  • 40 Pavie J, Lefort A, Zarrouk V , et al. Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics. Antimicrob Agents Chemother 2002; 46 (9) 3061-3064
    CrossrefPubMedGoogle Scholar
  • 41 Kang SL, Rybak MJ. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39 (Suppl A ): 33-39
    CrossrefPubMedGoogle Scholar
  • 42 Kang SL, Rybak MJ. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob Agents Chemother 1995; 39 (7) 1505-1511
    CrossrefPubMedGoogle Scholar
  • 43 Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46 (8) 2606-2612
    CrossrefPubMedGoogle Scholar
  • 44 Scotton PG, Rigoli R, Vaglia A. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens. Infection 2002; 30 (3) 161-163
    CrossrefPubMedGoogle Scholar
  • 45 Sgarabotto D, Cusinato R, Narne E , et al. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis 2002; 34 (2) 122-126
    CrossrefPubMedGoogle Scholar
  • 46 Paul M, Kariv G, Goldberg E , et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2010; 65 (12) 2658-2665
    CrossrefPubMedGoogle Scholar
  • 47 Chan KE, Warren HS, Thadhani RI , et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol 2012; 23 (9) 1551-1559
    CrossrefPubMedGoogle Scholar
  • 48 Chang FY, MacDonald BB, Peacock Jr JE , et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82 (5) 322-332
    CrossrefPubMedGoogle Scholar
  • 49 Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25 (3) 181-185
    CrossrefPubMedGoogle Scholar
  • 50 Schweizer ML, Furuno JP, Harris AD , et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11: 279
    CrossrefPubMedGoogle Scholar
  • 51 Klevens RM, Morrison MA, Nadle J , et al; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298 (15) 1763-1771
    CrossrefPubMedGoogle Scholar
  • 52 Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?. Clin Infect Dis 2008; 46 (6) 787-794
    CrossrefPubMedGoogle Scholar
  • 53 Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39 (3) 309-317
    CrossrefPubMedGoogle Scholar
  • 54 Seibert G, Isert D, Klesel N, Limbert M, Markus A, Schrinner E. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob Chemother 1992; 29 (Suppl A): 25-30
    CrossrefPubMedGoogle Scholar
  • 55 Palmer SM, Rybak MJ. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. J Antimicrob Chemother 1997; 39 (4) 515-518
    CrossrefPubMedGoogle Scholar
  • 56 Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999; 43 (7) 1747-1753
    PubMedGoogle Scholar
  • 57 Lozniewski A, Lion C, Mory F, Weber M. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother 2001; 47 (1) 83-86
    CrossrefPubMedGoogle Scholar
  • 58 Domaracki BE, Evans AM, Venezia RA. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother 2000; 44 (5) 1394-1396
    CrossrefPubMedGoogle Scholar
  • 59 Drago L, De Vecchi E, Nicola L, Gismondo MR. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis 2007; 7: 111
    CrossrefPubMedGoogle Scholar
  • 60 Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 2005; 11 (5) 259-261
    CrossrefPubMedGoogle Scholar
  • 61 Ribes S, Pachón-Ibáñez ME, Domínguez MA , et al. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides. Eur J Clin Microbiol Infect Dis 2010; 29 (11) 1361-1367
    CrossrefPubMedGoogle Scholar
  • 62 Joukhadar C, Pillai S, Wennersten C, Moellering Jr RC, Eliopoulos GM. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54 (2) 773-777
    CrossrefPubMedGoogle Scholar
  • 63 Silva LV, Araújo MT, Santos KR, Nunes AP. Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains. Mem Inst Oswaldo Cruz 2011; 106 (1) 44-50
    PubMedGoogle Scholar
  • 64 Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56 (1) 202-207
    CrossrefPubMedGoogle Scholar
  • 65 Fernandez J, Abbanat D, Shang W , et al. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56 (3) 1476-1484
    CrossrefPubMedGoogle Scholar
  • 66 Leonard SN. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. PLoS ONE 2012; 7 (7) e42103
    CrossrefPubMedGoogle Scholar
  • 67 Dilworth TJ, Sliwinski J, Ryan K, Dodd M, Mercier RC. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro. Antimicrob Agents Chemother 2014; 58 (2) 1028-1033
    CrossrefPubMedGoogle Scholar
  • 68 Werth BJ, Steed ME, Kaatz GW, Rybak MJ. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the “seesaw effect”. Antimicrob Agents Chemother 2013; 57 (6) 2664-2668
    CrossrefPubMedGoogle Scholar
  • 69 Werth BJ, Vidaillac C, Murray KP , et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother 2013; 57 (5) 2376-2379
    CrossrefPubMedGoogle Scholar
  • 70 Snydman DR, McDermott LA, Jacobus NV. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemother 2005; 17 (6) 614-621
    CrossrefPubMedGoogle Scholar
  • 71 Silva M, Jacobus NV, Gorbach SL. In vitro activity of LY146032 against gram-positive bacteria. Diagn Microbiol Infect Dis 1988; 9 (2) 79-85
    CrossrefPubMedGoogle Scholar
  • 72 Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48 (8) 2871-2875
    CrossrefPubMedGoogle Scholar
  • 73 Mehta S, Singh C, Plata KB , et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012; 56 (12) 6192-6200
    CrossrefPubMedGoogle Scholar
  • 74 Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother 2006; 18 (1) 27-32
    CrossrefPubMedGoogle Scholar
  • 75 Barber KE, Werth BJ, Ireland CE , et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother 2014; 69 (11) 3006-3010
    CrossrefPubMedGoogle Scholar
  • 76 Leonard SN, Rolek KM. Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother 2013; 68 (3) 644-647
    CrossrefPubMedGoogle Scholar
  • 77 Rose WE, Schulz LT, Andes D , et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012; 56 (10) 5296-5302
    CrossrefPubMedGoogle Scholar
  • 78 Werth BJ, Barber KE, Ireland CE, Rybak MJ. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 2014; 58 (6) 3177-3181
    CrossrefPubMedGoogle Scholar
  • 79 Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57 (1) 66-73
    CrossrefPubMedGoogle Scholar
  • 80 Garrigós C, Murillo O, Lora-Tamayo J , et al. Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56 (7) 3806-3811
    CrossrefPubMedGoogle Scholar
  • 81 Dhand A, Bayer AS, Pogliano J , et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53 (2) 158-163
    CrossrefPubMedGoogle Scholar
  • 82 Sakoulas G, Moise PA, Casapao AM , et al. Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline. Clin Ther 2014;
    PubMedGoogle Scholar
  • 83 Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the “seesaw effect”: Taking advantage of the back door left open?. Drug Resist Updat 2013; 16 (3-5) 73-79
    CrossrefPubMedGoogle Scholar
  • 84 Adhikari RP, Scales GC, Kobayashi K, Smith JM, Berger-Bächi B, Cook GM. Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus. J Antimicrob Chemother 2004; 54 (2) 360-363
    CrossrefPubMedGoogle Scholar
  • 85 Sieradzki K, Wu SW, Tomasz A. Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus. Microb Drug Resist 1999; 5 (4) 253-257
    CrossrefPubMedGoogle Scholar
  • 86 Sakoulas G, Okumura CY, Thienphrapa W , et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl) 2014; 92 (2) 139-149
    CrossrefPubMedGoogle Scholar
  • 87 Tuazon CU, Lin MY, Sheagren JN. In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13 (5) 759-761
    CrossrefPubMedGoogle Scholar
  • 88 Bahl D, Miller DA, Leviton I , et al. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41 (6) 1293-1297
    PubMedGoogle Scholar
  • 89 Mandell GL. Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest 1973; 52 (7) 1673-1679
    CrossrefPubMedGoogle Scholar
  • 90 Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am 2003; 17 (3) 615-634
    CrossrefPubMedGoogle Scholar
  • 91 Saginur R, Stdenis M, Ferris W , et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50 (1) 55-61
    CrossrefPubMedGoogle Scholar
  • 92 Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168 (8) 805-819
    CrossrefPubMedGoogle Scholar
  • 93 Mandell GL. Uptake, transport, delivery, and intracellular activity of antimicrobial agents. Pharmacotherapy 2005; 25 (12, Pt 2) 130S-133S
    CrossrefPubMedGoogle Scholar
  • 94 Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50 (3) 841-851
    CrossrefPubMedGoogle Scholar
  • 95 Zinner SH, Lagast H, Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis 1981; 144 (4) 365-371
    CrossrefPubMedGoogle Scholar
  • 96 Norden CW, Shaffer M. Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin. J Infect Dis 1983; 147 (2) 352-357
    CrossrefPubMedGoogle Scholar
  • 97 Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26 (2) 220-223
    CrossrefPubMedGoogle Scholar
  • 98 Varaldo PE, Debbia E, Schito GC. In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species. Antimicrob Agents Chemother 1985; 27 (4) 615-618
    CrossrefPubMedGoogle Scholar
  • 99 Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29 (4) 611-613
    CrossrefPubMedGoogle Scholar
  • 100 Walsh TJ, Auger F, Tatem BA, Hansen SL, Standiford HC. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin. J Antimicrob Chemother 1986; 17 (1) 75-82
    CrossrefPubMedGoogle Scholar
  • 101 Lucet JC, Herrmann M, Rohner P, Auckenthaler R, Waldvogel FA, Lew DP. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34 (12) 2312-2317
    CrossrefPubMedGoogle Scholar
  • 102 Tang HJ, Chen CC, Cheng KC , et al. In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57 (11) 5717-5720
    CrossrefPubMedGoogle Scholar
  • 103 Niska JA, Shahbazian JH, Ramos RI, Francis KP, Bernthal NM, Miller LS. Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection. Antimicrob Agents Chemother 2013; 57 (10) 5080-5086
    CrossrefPubMedGoogle Scholar
  • 104 Henry NK, Rouse MS, Whitesell AL, McConnell ME, Wilson WR. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82 (4A): 73-75
    PubMedGoogle Scholar
  • 105 Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994; 33 (5) 959-967
    CrossrefPubMedGoogle Scholar
  • 106 Chuard C, Herrmann M, Vaudaux P, Waldvogel FA, Lew DP. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991; 35 (12) 2611-2616
    CrossrefPubMedGoogle Scholar
  • 107 Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985; 151 (1) 157-165
    CrossrefPubMedGoogle Scholar
  • 108 Hessen MT, Pitsakis PG, Kaye D. Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34 (6) 1143-1145
    CrossrefPubMedGoogle Scholar
  • 109 Perdikaris G, Giamarellou H, Pefanis A, Donta I, Karayiannakos P. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob Agents Chemother 1995; 39 (10) 2289-2294
    CrossrefPubMedGoogle Scholar
  • 110 Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115 (9) 674-680
    CrossrefPubMedGoogle Scholar
  • 111 Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52 (7) 2463-2467
    CrossrefPubMedGoogle Scholar
  • 112 Jung YJ, Koh Y, Hong SB , et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38 (1) 175-180
    CrossrefPubMedGoogle Scholar
  • 113 Thwaites G, Auckland C, Barlow G , et al; United Kingdom Clinical Infection Research Group. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial. Trials 2012; 13: 241
    CrossrefPubMedGoogle Scholar
  • 114 Auwera Van der P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985; 28 (4) 467-472
    CrossrefPubMedGoogle Scholar
  • 115 Van der Auwera P, Meunier-Carpentier F, Klastersky J. Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis 1983; 5 (Suppl 3): S515-S522
    PubMedGoogle Scholar
  • 116 Johnson AP, Davies J, Guy R , et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother 2012; 67 (4) 802-809
    CrossrefPubMedGoogle Scholar
  • 117 Peel TN, Buising KL, Dowsey MM , et al. Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother 2013; 57 (1) 350-355
    CrossrefPubMedGoogle Scholar
  • 118 Aboltins CA, Page MA, Buising KL , et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007; 13 (6) 586-591
    CrossrefPubMedGoogle Scholar
  • 119 Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Foreign-Body Infection (FBI) Study Group. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 1998; 279 (19) 1537-1541
    CrossrefPubMedGoogle Scholar
  • 120 Senneville E, Joulie D, Legout L , et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011; 53 (4) 334-340
    CrossrefPubMedGoogle Scholar
  • 121 El Helou OC, Berbari EF, Lahr BD , et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29 (8) 961-967
    CrossrefPubMedGoogle Scholar
  • 122 Lora-Tamayo J, Murillo O, Iribarren JA , et al; REIPI Group for the Study of Prosthetic Infection. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2013; 56 (2) 182-194
    CrossrefPubMedGoogle Scholar
  • 123 Eisen DP, Denholm JS. Recommendations for rifampicin therapy of staphylococcal infection in Infectious Diseases Society of America prosthetic Joint Infection Guidelines are not supported by available literature. Clin Infect Dis 2013; 57 (1) 159-160
    CrossrefPubMedGoogle Scholar
  • 124 Osmon DR, Berbari EF, Berendt AR , et al; Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56 (1) 1-10
    PubMedGoogle Scholar
  • 125 LaPlante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009; 53 (9) 3880-3886
    CrossrefPubMedGoogle Scholar
  • 126 Miró JM, García-de-la-Mària C, Armero Y , et al; Hospital Clinic Experimental Endocarditis Study Group. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53 (10) 4172-4177
    CrossrefPubMedGoogle Scholar
  • 127 Rose WE, Berti AD, Hatch JB, Maki DG. Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2013; 57 (7) 3450-3452
    CrossrefPubMedGoogle Scholar
  • 128 Jugun K, Vaudaux P, Garbino J , et al. The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. Int Orthop 2013; 37 (7) 1375-1380
    CrossrefPubMedGoogle Scholar
  • 129 Lora-Tamayo J, Parra-Ruiz J, Rodríguez-Pardo D , et al. High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis 2014; 80 (1) 66-71
    CrossrefPubMedGoogle Scholar
  • 130 Watanakunakorm C, Glotzbecker C. Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother 1974; 6 (6) 802-806
    CrossrefPubMedGoogle Scholar
  • 131 Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41 (11) 2497-2501
    PubMedGoogle Scholar
  • 132 Lemonovich TL, Haynes K, Lautenbach E, Amorosa VK. Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study. Infection 2011; 39 (6) 549-554
    CrossrefPubMedGoogle Scholar
  • 133 Cosgrove SE, Vigliani GA, Fowler Jr VG , et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48 (6) 713-721
    CrossrefPubMedGoogle Scholar
  • 134 Baltch AL, Ritz WJ, Bopp LH, Michelsen PB, Smith RP. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51 (4) 1559-1562
    CrossrefPubMedGoogle Scholar
  • 135 Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007; 51 (4) 1504-1507
    CrossrefPubMedGoogle Scholar
  • 136 Debbia E, Pesce A, Schito GC. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob Agents Chemother 1988; 32 (2) 279-281
    CrossrefPubMedGoogle Scholar
  • 137 LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48 (12) 4665-4672
    CrossrefPubMedGoogle Scholar
  • 138 DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother 2006; 50 (11) 3529-3534
    CrossrefPubMedGoogle Scholar
  • 139 Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52 (9) 3061-3067
    CrossrefPubMedGoogle Scholar
  • 140 Baltch AL, Ritz WJ, Bopp LH, Michelsen P, Smith RP. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob Agents Chemother 2008; 52 (5) 1829-1833
    CrossrefPubMedGoogle Scholar
  • 141 Kullar R, Casapao AM, Davis SL , et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother 2013; 68 (12) 2921-2926
    CrossrefPubMedGoogle Scholar
  • 142 Steed ME, Werth BJ, Ireland CE, Rybak MJ. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 2012; 56 (11) 5709-5714
    CrossrefPubMedGoogle Scholar
  • 143 Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ. Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2012; 56 (11) 5990-5993
    CrossrefPubMedGoogle Scholar
  • 144 Di Carlo P, D'Alessandro N, Guadagnino G , et al. High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Infez Med 2013; 21 (1) 45-49
    PubMedGoogle Scholar
  • 145 Dumitrescu O, Badiou C, Bes M , et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008; 14 (4) 384-388
    CrossrefPubMedGoogle Scholar
  • 146 Dumitrescu O, Boisset S, Badiou C , et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007; 51 (4) 1515-1519
    CrossrefPubMedGoogle Scholar
  • 147 Diep BA, Afasizheva A, Le HN , et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 2013; 208 (1) 75-82
    CrossrefPubMedGoogle Scholar
  • 148 Rouzic N, Janvier F, Libert N , et al. Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes. J Clin Microbiol 2010; 48 (5) 1952-1955
    CrossrefPubMedGoogle Scholar
  • 149 Li HT, Zhang TT, Huang J, Zhou YQ, Zhu JX, Wu BQ. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration 2011; 81 (6) 448-460
    CrossrefPubMedGoogle Scholar
  • 150 Subedi S, Baird R, Tong SY. Does the Addition of Lincosamides Have Mortality Benefit in Severe Staphylococcal Infection? C-765. In: Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014; Washington, DC; 2014
    PubMedGoogle Scholar
  • 151 Gillet Y, Dumitrescu O, Tristan A , et al. Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents 2011; 38 (6) 457-464
    CrossrefPubMedGoogle Scholar
  • 152 Health Protection Agency. Guidance on the Diagnosis and Management of PVL-Associated Staphylococcus aureus Infections (PVL-SA) in England, 2nd ed. London, UK: HPA; 2008
    CrossrefGoogle Scholar
  • 153 Lin G, Pankuch G, Appelbaum PC, Kosowska-Shick K. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob Agents Chemother 2014; 58 (10) 6251-6254
    CrossrefPubMedGoogle Scholar
  • 154 Lin G, Pankuch GA, Ednie LM, Appelbaum PC. Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother 2010; 54 (5) 2201-2205
    CrossrefPubMedGoogle Scholar
  • 155 Xu-hong Y, Falagas ME, Dong W, Karageorgopoulos DE, De-feng L, Rui W. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo) 2014; 67 (5) 369-371
    CrossrefPubMedGoogle Scholar